Novavax Extends Key Production Agreement with Mabion Through 2029
NVAX sits 56% above its 52-week low of $6.13.
Summary
Novavax has extended its production agreement with Mabion until the end of 2029. This multi-year extension provides important operational stability and ensures continued manufacturing capacity for Novavax's products. The news follows Novavax's recent Q1 report, which showed a net loss but also highlighted a new credit facility and a significant licensing agreement with Pfizer, indicating a focus on securing its financial and operational future.
At the time of this announcement, NVAX was trading at $9.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.13 to $11.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.